Findings suggest drug has prospective to decrease danger of heart disease, stroke, and diabetes.
In grownups with weight problems or obese, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide causes decreased excess body fat and increased lean body mass, according to an industry-sponsored study presented practically at ENDO 2021, the Endocrine Societys annual conference.
” Our findings suggest that semaglutide, through body weight loss and enhancement of body structure, has the potential to decrease the risk of heart problem, diabetes, and stroke in individuals with obese or obesity,” said lead researcher John Wilding, D.M., F.R.C.P., of the University of Liverpool.
The research study participants were arbitrarily assigned to inject themselves when weekly for 68 weeks with either 2.4 milligrams of semaglutide or a placebo. Semaglutide, already approved by the U.S. Food and Drug Administration at the lower dose of 1 mg weekly as a treatment for type 2 diabetes, is an artificial version of the naturally occurring hormonal agent glucagon-like peptide 1 (GLP1). More than one-third of individuals receiving semaglutide lost more than 20% of their weight.
Obesity presents numerous health threats. Excess fat in the abdominal area, particularly fat around stomach organs, likewise called visceral fat, adds to significant causes of death and impairment, including cardiac arrest, strokes, hypertension, cancer, fatty liver illness and diabetes.
The research study, called STEP 1, consisted of 1,961 adults with a body mass index (BMI) of 27 or greater with a minimum of one weight-related health condition, or a BMI of 30 or greater, without diabetes. A person is categorized as overweight if their BMI is 25 to 29.9, and the variety for weight problems is a BMI of 30 or more.
When weekly for 68 weeks with either 2.4 milligrams of semaglutide or a placebo, the research study participants were randomly appointed to inject themselves. Semaglutide, already authorized by the U.S. Food and Drug Administration at the lower dose of 1 mg weekly as a treatment for type 2 diabetes, is an artificial variation of the naturally happening hormonal agent glucagon-like peptide 1 (GLP1). It acts upon hunger centers in the brain and in the gut, and produces sensations of fullness.
As part of the research study, the researchers utilized dual-energy absorptiometry (DEXA), a technique that is widely used scientifically to assess body structure, to monitor the effects of therapy on total body fat and fat around the stomach area in 140 of the participants.
They discovered treatment with semaglutide improved body composition by minimizing excess body fat, consisting of stomach fat, and increasing the percentage of lean body mass, or the quantity of weight somebody carries that is not body fat. The more body weight an individual lost, the higher the improvement in body composition.
In February 2021, the scientists published findings from the STEP 1 trial in The New England Journal of Medicine revealing that clients who injected semaglutide lost near to 15% of their body weight, usually, compared with 2.4% among clients receiving the placebo. More than one-third of participants getting semaglutide lost more than 20% of their weight. Numerous patients experienced enhancements in risk elements for heart illness, blood sugar levels and quality of life.
Satisfying: ENDO 2021